



## Regulatory Announcement

[Go to market news section](#)

Free annual report  

**Company** Cobra Bio-Manufacturing PLC  
**TIDM** CBF  
**Headline** Manufacturing Agreement  
**Released** 07:00 01-Feb-07  
**Number** 4992Q



**For Immediate Release**

**1 February 2007**

### Cobra Biomanufacturing Plc

#### Manufacturing agreement with Pharmexa

**Keele, UK, 1 February 2007:** UK-based Cobra Biomanufacturing Plc (AIM: CBF) today announces an agreement with Pharmexa for the manufacture of the protein vaccine PX107 for use in Phase I clinical trials for bone disorders. The program will include cell banking, process development and GMP manufacture.

The protein will be manufactured by Cobra, which has earned a global reputation for the manufacturing of therapeutic proteins and vaccines, and has GMP manufacturing facilities in both Keele and Oxford, UK.

The therapeutic vaccine, PX107, makes use of Pharmexa's proprietary active immunotherapy technology, AutoVac™. Currently in preclinical development, PX107 induces a potent polyclonal antibody response towards the protein RANKL, which is increased or imbalanced in the body in diseases such as osteoporosis, rheumatoid arthritis and bone metastasis with pathological bone destruction.

Pharmexa will be carrying out the upstream and downstream development of PX107 but requires Cobra's cGMP manufacturing capabilities to produce the material for clinical Phase I trials.

**David Thatcher, Chief Executive of Cobra Biomanufacturing, commented:**

"We very much look forward to providing Pharmexa with our GMP manufacturing expertise to produce their promising vaccine candidate, PX107. The product will be manufactured at our Oxford site, which has recently been expanded."

-Ends-

**For further information, please contact:**

**Cobra Biomanufacturing Plc**  
David Thatcher, Chief Executive

**Tel: +44 (0) 1782 714 181**

**Buchanan Communications**  
Tim Anderson/Mark Court/Rebecca Skye Dietrich

**Tel: +44 (0) 207 466 5000**

**Northbank Communications**  
Gemma Bradley

**Tel: +44 (0) 203 008 7555**

**Notes to Editors:**

**About Cobra Biomanufacturing Plc:**

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra was the first company to develop GMP (Good Manufacturing Practice) standard DNA manufacture in Europe, with specific expertise in DNA medicines. A range of unique, patented technologies, underpins this revenue generating business. [www.cobrabio.com](http://www.cobrabio.com)

**About Pharmexa:**

Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, rheumatoid arthritis, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and is expected to enter a phase II trial in liver cancer soon, as well as a number of HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 100 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX. [www.pharmexa.com](http://www.pharmexa.com)

END

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.**

©2007 London Stock Exchange plc. All rights reserved